Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, Felix Health operates as a licensed telehealth platform, but legitimacy requires verification of provider credentials, pharmacy compliance, and clinical governance. Patients should confirm that any GLP-1 program partners with licensed pharmacies and maintains state-approved protocols.

Choosing a GLP-1 program involves more than checking licensure. Understanding your individual response profile—including genetic predispositions in GLP-1 and GIPR pathways—helps align treatment selection with clinical evidence and your metabolic context.

How to Verify Telehealth Platform Legitimacy

Legitimate telehealth platforms must obtain state medical board licensure, employ board-certified physicians, and partner with accredited pharmacies. Check the platform's website for provider credentials, pharmacy partnerships, and published treatment protocols. Request documentation of pharmacy licensing status.

Red flags include vague provider information, lack of state board verification, or partnerships with 503B outsourcing facilities instead of licensed 503A compounding pharmacies. State pharmacy boards maintain public databases where you can confirm pharmacy credentials independently.

Evaluating Provider Credentials and Clinical Standards

All GLP-1 prescribers should hold current medical licenses and board certification in relevant specialties. Verify licensure through your state's medical board website. Legitimate programs document provider training in weight management, metabolic assessment, and GLP-1 pharmacology.

Clinical standards include baseline metabolic screening, contraindication assessment, and regular follow-up protocols. Programs should define how they monitor for side effects, adjust dosing, and manage discontinuation. Provider-patient communication frequency varies but should be clearly disclosed upfront.

Credential Factor What to Verify
Provider Licensure Current MD/DO license in your state via state medical board database
Board Certification Specialty certification (Family Medicine, Bariatrics, Endocrinology preferred)
Pharmacy Compliance 503A compounding license; check state pharmacy board records
Treatment Protocols Written eligibility criteria, baseline labs, monitoring schedule, side effect management
Clinical Governance Medical director oversight and peer review processes documented

Pharmacy Partnerships and Medication Quality Standards

Legitimate GLP-1 programs partner with licensed 503A compounding pharmacies that operate under state oversight and undergo regular inspections. These pharmacies compound medications from FDA-approved ingredients under sterile conditions. Verify that your program does not use 503B outsourcing facilities.

Ask your provider which specific pharmacy will compound your medication and confirm its licensure status independently. Quality standards include pharmaceutical-grade ingredients, proper stability testing, and documented quality assurance procedures. Programs should disclose their pharmacy partnership transparently.

Who Should Use Telehealth GLP-1 Programs and Important Safety Considerations

Telehealth GLP-1 programs suit adults with BMI ≥27 kg/m² with weight-related conditions or BMI ≥30 kg/m² seeking weight management under medical supervision. Exclusions include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pregnancy, or uncontrolled diabetes requiring urgent intervention.

Before starting, baseline labs should include thyroid function, lipid panel, and glucose assessment. Regular provider contact ensures dose tolerance and side effect monitoring. Any telehealth program should offer clear escalation protocols if in-person evaluation becomes necessary.

How PlexusDx Supports a More Personalized Approach

Beyond verifying provider credentials, understanding your genetic predisposition in GLP-1 and GIPR pathways may help provide context for personalizing your GLP-1 response profile. PlexusDx's Precision Peptide Genetic Test examines key variants (GLP1R rs6923761, GIPR rs1800437) that influence baseline metabolism and potential treatment response patterns.

The genetic test does not predict exact medication response or guarantee outcomes. Instead, it reveals predispositions in peptide genetic pathways that should be interpreted with a qualified healthcare provider alongside clinical assessment. This information can support more informed provider conversations about dosing strategy and medication selection.

When evaluating any GLP-1 program, consider whether the provider integrates genetic and biomarker insights into their clinical decision-making. PlexusDx combines genetic assessment with compounded medications from licensed 503A pharmacies, enabling a data-informed approach to personalized weight management protocols.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How do I verify if a telehealth GLP-1 program is legitimate?

Check provider state medical board licensure, confirm partnerships with 503A compounding pharmacies via state pharmacy records, and review published clinical protocols. Ask for documentation of provider credentials and pharmacy compliance.

What is the difference between 503A and 503B pharmacies for compounded GLP-1 medications?

503A compounding pharmacies operate under state license and FDA oversight with regular inspections. 503B outsourcing facilities operate under federal exemption with less stringent oversight. Licensed programs should exclusively use 503A pharmacies.

Does PlexusDx offer a way to personalize GLP-1 treatment selection?

Yes. PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) examines key variants in GLP-1 and GIPR pathways. Results should be interpreted with your provider to inform treatment strategy and support personalized dosing decisions.

What baseline labs should a legitimate GLP-1 program require before starting treatment?

Standard assessment includes fasting glucose or HbA1c, lipid panel, thyroid function (TSH, free T4), and renal function. Blood pressure and BMI documentation are required. Some programs add additional screening based on personal or family history.

Can genetic testing predict whether I will succeed with GLP-1 treatment?

Genetic predispositions in peptide pathways provide context for individual variation in metabolism, but do not predict exact outcomes. PlexusDx's Precision Peptide Genetic Test reveals baseline predispositions that should guide provider conversations—not replace clinical judgment.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves